- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00103467
Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine
June 23, 2005 updated by: VaxGen
A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine
The purpose of this phase 1 study is to evaluate the safety and immunogenicity of rPA102 vaccine, using anthrax vaccine adsorbed (AVA) as a comparator.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
100
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Dept. of International Health - Johns Hopkins University Bloomberg School of Public Health
-
-
Missouri
-
St. Louis, Missouri, United States, 63104
- St. Louis University - SoLutions/SLUtest
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to understand the study and give written informed consent. A signed informed consent must be in place before the initiation of any study interventions.
- Healthy male or female aged 18 to 40 years old (inclusive) without significant physical or clinical laboratory abnormalities.
- Two intact upper arms with sufficient intramuscular (IM) tissue in the deltoid region for vaccine administration.
- For females, negative serum pregnancy test at screening and agreement to use adequate birth control during the first 3 months of the study.
- Willingness and ability to return for all follow-up visits and blood draws for the duration of the study.
- Willingness to complete the Volunteer Diary and to report concomitant medications and adverse events (AEs) to the study site monitors during the study period.
Exclusion Criteria:
- Prior history of, or known exposure to any form of B. anthracis or any anthrax immunization.
- Member of the Armed Services (Active Duty or Reserve) since 1990, with history of previous anthrax vaccination.
- Employment in an industry involved in contact with ruminant animals, veterinary sciences, or other exposure to B. anthracis.
- Expected to be noncompliant with study visits or planning to move within 8 months.
- Body mass index of >35 or <19.
- Known allergy to aluminum hydroxide, formaldehyde, benzethonium chloride, latex, kanamycin, or any other aminoglycoside antibiotics (such as gentamycin).
- Pregnancy (positive urine pregnancy test within 24 hours prior to vaccination), or lactation.
- HIV positive (by history or screening ELISA).
- Hepatitis B or C positive (by history or screening HBsAg/anti-HCV ELISA).
- Active or past internal organ, hematologic malignancy, or metastatic cutaneous malignancy.
- History of, or current autoimmune disease, including but not limited to systemic lupus erythematosus, scleroderma, and polyarteritis.
- Immunodeficiency or unstable medical condition as determined by baseline medical history, physical exam, and laboratory assessment.
- Received, or plans to receive, licensed live vaccines within 30 days of study vaccination.
- Received, or plans to receive, licensed killed vaccines within 14 days of study vaccination.
- Received, or plans to receive, immunoglobulin or other blood products within 60 days of study vaccination.
- Received, or plans to receive, experimental drugs/vaccines within 30 days of study vaccination.
- Received, or plans to receive, systemic immunosuppresive therapy, radiation therapy, or high-dose inhaled steroids within 30 days of study vaccination.
- Use of systemic chemotherapy within 5 years prior to study.
- History of Guillain-Barre Syndrome.
- In addition to the conditions listed above, the following may qualify as a reason to exclude a volunteer from the study: fever along with moderate or serious illness within 3 days of vaccination or any condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the study evaluations. Pending resolution of these symptoms, a volunteer may be reconsidered for vaccination.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety and immunogenicity of 3 doses over 4 different dose ranges.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2003
Study Registration Dates
First Submitted
February 8, 2005
First Submitted That Met QC Criteria
February 8, 2005
First Posted (Estimate)
February 9, 2005
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
February 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAX005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Anthrax Infection
-
PharmAthene UK LimitedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPrevention of Bacillus Anthracis (Anthrax) InfectionUnited Kingdom
-
Emergent BioSolutionsCompletedAnthrax InfectionUnited States
-
Emergent BioSolutionsNational Institute of Allergy and Infectious Diseases (NIAID); Department of...CompletedBacillus Anthracis (Anthrax) InfectionUnited States
-
Emergent BioSolutionsDepartment of Health and Human ServicesCompletedSymptoms of Inhalational AnthraxUnited States
-
TaiMed Biologics Inc.Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research CenterCompletedPrevention of Infection With HIV-1United States
-
Klein, Jeffrey A., M.D.Completed
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Merck Sharp & Dohme LLCCompletedCancer Survivor | Prevention of Human Papillomavirus InfectionUnited States
-
Human Genome Sciences Inc.GlaxoSmithKline; Emergent BioSolutionsCompletedTherapeutic Treatment of Inhalation Anthrax
-
Indiana University School of MedicineTerminatedInfection PreventionUnited States
Clinical Trials on rPA102 Vaccine
-
VaxGenNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsCompleted
-
Butantan InstituteUniversity of Sao Paulo; Hospital Universitario da USPCompleted
-
Sinovac Biotech Co., LtdCompleted
-
University of OxfordMalaria Research and Training Center, Bamako, MaliRecruiting
-
GlaxoSmithKlineCompletedMalaria | Malaria VaccinesGhana, Burkina Faso
-
GlaxoSmithKlineIQVIA, USAActive, not recruitingChickenpoxTaiwan, Poland, United States, Estonia, Puerto Rico, Mexico
-
Sun XinActive, not recruitingVaccine Adverse ReactionChina
-
GlaxoSmithKlineCompletedInfections, PapillomavirusFinland
-
University of California, San FranciscoCompletedHematopoietic Stem Cell TransplantUnited States
-
University of PretoriaUniversity of StellenboschActive, not recruiting